Equities analysts forecast that Aptevo Therapeutics Inc (NASDAQ:APVO) will announce earnings of ($0.57) per share for the current quarter, Zacks reports. Two analysts have provided estimates for Aptevo Therapeutics’ earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.60). The company is scheduled to report its next earnings report on Tuesday, March 12th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full-year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($2.37) to ($2.27). For the next financial year, analysts forecast that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.71) to ($1.71). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.01. The firm had revenue of $5.82 million during the quarter, compared to analysts’ expectations of $6.87 million. Aptevo Therapeutics had a negative net margin of 252.44% and a negative return on equity of 78.85%.

Several equities analysts have recently weighed in on APVO shares. ValuEngine lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Roth Capital set a $12.00 price objective on shares of Aptevo Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 15th. Zacks Investment Research lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. Finally, LADENBURG THALM/SH SH started coverage on shares of Aptevo Therapeutics in a research report on Monday, November 5th. They issued a “buy” rating and a $14.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Aptevo Therapeutics presently has an average rating of “Buy” and a consensus target price of $10.69.

APVO stock traded down $0.10 during trading hours on Thursday, reaching $1.77. The stock had a trading volume of 61,600 shares, compared to its average volume of 128,646. The stock has a market cap of $40.37 million, a P/E ratio of -1.16 and a beta of 3.08. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.91 and a quick ratio of 3.65. Aptevo Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $6.35.

Several institutional investors and hedge funds have recently modified their holdings of APVO. Northern Trust Corp raised its position in shares of Aptevo Therapeutics by 21.2% in the second quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 12,299 shares during the period. Acadian Asset Management LLC raised its position in shares of Aptevo Therapeutics by 4.8% in the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 21,059 shares during the period. Sessa Capital IM L.P. raised its position in shares of Aptevo Therapeutics by 35.9% in the third quarter. Sessa Capital IM L.P. now owns 706,613 shares of the biotechnology company’s stock valued at $3,590,000 after purchasing an additional 186,719 shares during the period. Renaissance Technologies LLC raised its position in shares of Aptevo Therapeutics by 53.3% in the second quarter. Renaissance Technologies LLC now owns 1,149,400 shares of the biotechnology company’s stock valued at $5,736,000 after purchasing an additional 399,400 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Aptevo Therapeutics by 10.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,351,656 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 131,804 shares during the period. 32.59% of the stock is currently owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Featured Story: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.